| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Duker Jay S. | President and CEO, Director | C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN | /s/ Ron Honig, Attorney-in-Fact | 25 Jun 2025 | 0001630864 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EYPT | Common Stock | Other | $465,220 | -56,665 | -98% | $8.21 | 986 | 23 Jun 2025 | Direct | F1 |
| holding | EYPT | Common Stock | 99,165 | 23 Jun 2025 | By Family Trust | F2 |
| Id | Content |
|---|---|
| F1 | The shares were sold by the reporting person to the Duker Family 2024 Irrevocable Trust, or the Family Trust, in exchange for a promissory note in the principal amount of $465,219.65, representing the fair market value as determined by utilizing the average of the high and low per share trading price on the date of the sale. The shares held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F2 | These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |